AI assistant
LISATA THERAPEUTICS, INC. — Director's Dealing 2015
Jul 2, 2015
34931_dirs_2015-07-02_a6a3d003-b2b2-4afe-b33b-5f7f38d9b3c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2015-06-30
Reporting Person: Pecora Andrew L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-06-30 | Common Stock, $0.001 par value | A | 6702 | $1.5895 | Acquired | 364658 | Direct |
| 2015-06-30 | Common Stock, $0.001 par value | A | 227 | $1.87 | Acquired | 364885 | Direct |
| 2015-07-02 | Common Stock, $0.001 par value | A | 2097 | $1.89 | Acquired | 366982 | Direct |
Footnotes
F1: Shares purchased pursuant to Caladrius Biosciences, Inc.'s 2012 Employee Stock Purchase Plan for the period ended June 30, 2015.
F2: Effective August 15, 2013, the Issuer's Board of Directors approved an arrangement whereby the Reporting Person shall receive a portion of his net salary through the issuance to him by the Issuer of shares of the Issuer's common stock, $.001 par value (the "Common Stock") at the then-market price at the time of issuance, under and subject to the terms and conditions of the Issuers' Amended & Restated 2009 Equity Compensation Plan (the "Plan").